Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.,Breast Cancer Res Treat,174 (3):639-647.

Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.,J Cancer Res Clin Oncol,145(5):1235-1242

Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.,Int J Cancer,146(2):487-495

Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients.,Cancer Sci,110 (10):3368-3374

Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negativebreast cancer patients.,Breast Cancer Res Treat,2020;179(3):605-614.

Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers in a Large Cohort of Unselected Chinese Breast Cancer Patients.,Int J Cancer,2020;146(12):3335-3342.

BRCA1 c.5470_5477del, a Founder Mutation in Chinese Han Breast Cancer Patients.,Int J Cancer,2020;146(11):3044-3052

HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.,Cancer Sci,2017,108(4):671-677

Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients.,Clin Cancer Res,2017,23(20):6113-6119

HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negativebreast cancer. ,Oncol Lett ,2017;13(5):3793-3798

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer. ,Breast Cancer Res Treat ,2016,158(3):455–462

Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. ,Breast Cancer Res Treat ,156(3):441-5

A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients. ,Oncotarget ,7(4):5042-52

Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer. ,Gene ,584(1):26-30

TP53 Mutations Are Associated with Higher Rates of Pathologic Complete Response to Anthracycline/Cyclophosphamide-Based Neoadjuvant Chemotherapy in Operable Primary Breast Cancer. ,Int J Cancer ,138(2):489-96

Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer. ,Chin J Cancer Res ,27(6):553-61

RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients.,Int J Cancer.,143(8):1935-1942

Prevalence of BRCA1/2 large genomic rearrangements in Chinese women with sporadic triple-negative or familial breast cancer.,Clin Genet,94(1):165-169.

乳腺癌个体化治疗

乳腺癌易感基因RECQL致瘤机制及潜在分子靶点的研究, 课题负责人 , 2020.1.1～2023.12.31, 国家自然科学基金委员会面上项目

科技北京百名领军人才培养工程 , 课题负责人 , 2016.1.1～2018.12.31, 北京市科委 LJ201629

乳腺癌个体化治疗的临床与基础研究 , 课题负责人 , 2014.1.1～2017.12.31, 科技部十二五支撑计划项目 2014BAI09B08

中国汉族乳腺癌BRCA1/2始祖突变的鉴定及功能研究 , 课题负责人 , 2014.1.1～2017.12.31, 国家自然基金 81372832

DNA损伤修复蛋白在家族性乳腺癌早诊和辅助化疗中的应用 , 子课题负责人 , 2013.3.13～2017.8.31, 科技部973项目/2013CB911004